跳至主要内容
临床试验/CTRI/2021/10/037627
CTRI/2021/10/037627尚未招募3 期

Efficacy and safety of ADD-ON intravenous Ketamine in DSM-V diagnosed severe depressive disorder;a double blind controlled trial. - DEPKET

KIMS0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方
KIMS

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Patients diagnosed with severe depression according to the DSM-5 guidelines and ham-d score suggesting Depression.
  • Patients who give their consent

排除标准

  • 1.Patients with present diagnosis or antecedents of clinically relevant cardiovascular disorder such as stroke, heart attack,etc
  • 2.Patients with present or past diagnosis of glaucoma, intracranial hypertension
  • 3.Patients with current diagnosis of schizophrenia and related disorder
  • 4.Significant ECG abnormalities
  • 5.History of neurological disease or prior head trauma with evidence of cognitive impairment
  • 6.Known hypersensitivity to ketamine
  • 7.Patients who donot give their informed consent

研究者

发起方
KIMS

相似试验